Clearmind announces results from preclinical trial of MEAI with SciSparc’s PEA

Clearmind Medicine announced results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem, earlier this week. The treatment used in the trial combined Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions, obesity and metabolic disorders and depression, and SciSparc’s Palmitoylethanolamide, which is an anti-inflammatory agent and the active ingredient of its proprietary CannAmide. The goal of the trial was to identify the optimal dosage for their combination, to observe their safety and impact on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Fourteen different treatment groups were created receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a remarkable degree of tolerance, leaving the animals’ viability unaffected across all experimental groups. Similar results were also observed in groups treated by the combination of MEAI and PEA with the most prominent effects being observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated that: The administered treatment exhibited a remarkable degree of tolerance, leaving the mice’ viability unaffected across all experimental groups. Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. Oxygen consumption and carbon dioxide emission indicates increase in metabolic process and fat burn. A striking reduction in food consumption and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted, particularly at 20 and 10 mg/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity.